TrialDiabetes care2025
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.
Timothy E Graham et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
TrialDiabetes care2025
Timothy E Graham et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.